Blog
RSS FeedPosted by Michael Wonder on 25 May 2022
Health economic assessment of Trodelvy in advanced triple negative breast cancer
23 May 2022 - TLV has produced a health economic assessment for the regions for the drug Trodelvy (sacituzumab govitecan). ...
Posted by Michael Wonder on 30 Jan 2022
Trade-offs and policy options - using insights from economics to inform public health policy
29 January 2022 - We believe that economics can critically inform public health efforts to address such challenges. ...
Posted by Michael Wonder on 10 Nov 2020
ICER provides second update to pricing models for remdesivir as a treatment for COVID-19
10 November 2020 - Based on an analysis of four studies evaluating remdesivir’s influence on mortality, ICER has concluded that the ...
Posted by Michael Wonder on 07 Nov 2020
A health opportunity cost threshold for cost effectiveness analysis in the United State
3 November 2020 - Cost effectiveness analysis is an important tool for informing treatment coverage and pricing decisions, yet no consensus ...
Posted by Michael Wonder on 09 Jan 2020
Should access to life saving medicines be determined by economic evaluations?
9 January 2020 - Time is the most precious commodity all of us have. ...
Posted by Michael Wonder on 18 Nov 2019
Improving transparency in decision models: current issues and potential solutions
23 October 2019 - Decision-analytic models have become an essential tool used to inform health technology assessments. ...
Posted by Michael Wonder on 27 Jul 2019
A non-inferiority framework for cost-effectiveness analysis
24 July 2019 - Traditional decision rules have limitations when a new technology is less effective and less costly than a ...
Posted by Michael Wonder on 20 Jun 2019
Novel approaches to value assessment within the cost-effectiveness framework
20 June 2019 - The second plenary session focused on the need to move beyond conventional cost-effectiveness analysis of healthcare interventions ...
Posted by Michael Wonder on 15 Jun 2019
New cost-effectiveness methods to determine value-based prices for potential cures: what are the options?
12 June 2019 - Evaluating different approaches to assessing the clinical effectiveness and value of potential cures will be essential to ...
Posted by Michael Wonder on 12 Jun 2019
Incorporating future medical costs: impact on cost-effectiveness analysis in cancer patients
12 June 2019 - The inclusion of future medical costs in cost-effectiveness analyses remains a controversial issue. ...
Posted by Michael Wonder on 29 May 2019
Cost effectiveness analysis in the context of US commercial health insurance
29 May 2019 - Discussions of the cost effectiveness of medical services often are couched in the framework of a ...
Posted by Michael Wonder on 20 Apr 2019
Expanding the scope of costs and benefits for economic evaluations in health: some words of caution
18 April 2019 - Discussions regarding the appropriate scope of costs and benefits for inclusion in economic evaluation in healthcare have ...
Posted by Michael Wonder on 22 Feb 2019
Choosing a time horizon in cost and cost-effectiveness analyses
21 February 2019 - When designing a comparative outcomes or a cost-effectiveness analysis, the time horizon defining the duration of time ...
Posted by Michael Wonder on 23 Jan 2019
Future costs in cost-effectiveness analyses: past, present, future
23 January 2019 - There has been considerable debate on the extent to which future costs should be included in cost-effectiveness ...
Posted by Michael Wonder on 19 Nov 2018
Which databases should be used to identify studies for systematic reviews of economic evaluations?
16 November 2018 - This study investigated which databases and which combinations of databases should be used to identify economic evaluations ...